Talazoparib plus enzalutamide before prostate surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate adenocarcinoma (a common prostate cancer type) that the urologist thinks can be removed with surgery after this pre-surgery treatment
- Your healthcare team considers you medically fit for surgery, and you plan to have a radical prostatectomy at the end of treatment
- Your cancer has shown spread to lymph nodes (or has certain lymph node findings on scans), but not to bone or other organs
- You are well enough to do daily activities (ECOG 2 or better) and can follow study visits, tests, and treatment plans
- Your blood counts and organ function (liver, kidneys) meet safety lab thresholds, and you have no blood-scan signs of certain blood cancers like MDS/AML
- You can provide tumor tissue samples (old biopsy blocks and new samples at set times) for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.